業績

Tsuzuki A, Fujioka Y, Yoshida A, Kashiwagi S, Amano M, Hira T, Nakamura A, Miyoshi H, Atsumi T, Ohba Y.

Direct visualization of GLP-1 secretion by fluorescent fusion proteins.

J Diabetes Invest. 2022, in press

IF 4.232

Cho KY, Miyoshi H, Nakamura A, Greenberg AS, Atsumi T.

Lipid droplet protein PLIN1 regulates inflammatory polarity in human macrophages and is involved in atherosclerotic plaque development by promoting stable lipid storage.

J Atheroscler Thromb, in press

IF: 4.928

Nakamura A.

Glucokinase as a therapeutic target based on findings from the analysis of mouse models.

Endocr J, in press

IF: 2.349

公益財団法人 福田記念医療技術振興財団　論文等表彰事業　優秀賞　亀田　玲奈先生

Shibayama Y, Alkhoury C, Nemazanyy I, Henneman N, Cagnard N, Girard M, Atsumi T, Panasyuk G.

Class 3 Phosphatidyl Inositol-3 Kinase Promotes Hepatic Glucocorticoid Receptor Stability and Transcriptional Activity Acta Physiologica, in press

IF: 6.311

Yuki Oe, Hiroshi Nomoto, Akinobu Nakamura, Saki Kuwabara, Yuka Takahashi, Ayano Yasui, Rimi Izumihara, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi Switching from insulin degludec plus dipeptidyl peptidase-4 inhibitor to insulin degludec/liraglutide improves glycemic variability in patients with type 2 diabetes: a preliminary prospective observation study J Diabetes Res, in press.

IF: 4.011

Takahashi Y, Kameda H, Miya A, Nomoto H, Nakamura A, Nishimura H, Kimura H, Suzuki M, Konno S, Shimizu A, Matsuno Y, Okamoto M, Motegi H, Iwata N, Fujisawa H, Suzuki A, Sugimura Y, Miyoshi H, A tsumi T.

Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis.

Pituitary, in press.

IF: 4.107

Oe Y, Kameda H, Nomoto H, Sakamoto K, Soyama T, Cho KY, Nakamura A, Iwasaki K, Abo D, Kudo K, Miyoshi H, Atsumi T.

Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: a case report Medicine, in press

IF: 1.889

第47回日本神経内分泌学会　若手研究奨励賞　関崎　知紀先生

Kamoshima H, Nomoto H, Yamashita K, Takahashi Y, Tsuchida K, Kuwabara S, Miya A, Cho KY, Kameda H, Nakamura A, Atsumi T, Taneda S, Kurihara Y, Aoki S, Ono Y, Miyoshi H.

Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?

Endocrine Journal, in press.

IF: 2.349